Analyst: Rite Aid Faces Integration Hurdles
Rite Aid Corp. (RAD)'s stock price has surged in recent months as investors bet on the drugstore chain's turnaround. Goldman Sachs (GS) isn't so sure that collective wisdom is correct. Goldman analyst John Heinbockel is skeptical and downgraded Rite Aid shares to sell from neutral on Jan. 19. He thinks the Camp Hill, Pa.-based company's plan to buy the Brooks and Eckerd drugstore chains from The Jean Coutu Group (PJC) Inc. could bring trouble.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.